Alaunos Therapeutics (TCRT) Non-Current Deffered Revenue (2009 - 2018)
Alaunos Therapeutics' (TCRT) quarterly Non-Current Deffered Revenue came in at $4000.0 in Q4 2018, down 97.18% YoY from $142000.0 in Q4 2017, and down 33.33% on a QoQ basis from $6000.0 in Q3 2018.
Alaunos Therapeutics (TCRT) Non-Current Deffered Revenue (2009 - 2018) Analysis & Trends
Alaunos Therapeutics (TCRT) has 10 years of Non-Current Deffered Revenue data on file, last reported at $4000.0 in Q4 2018.
- Quarterly Non-Current Deffered Revenue fell 97.18% year-over-year to $4000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $4000.0 (down 97.18% YoY) and the FY2018 annual result came in at $4000.0, down 97.18% from the prior year.
- Non-Current Deffered Revenue fell to $4000.0 in Q4 2018, from $6000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $49.5 million in Q2 2018 to a low of $4000.0 in Q4 2018.
- A 5-year average of $7.4 million and a median of $401000.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2017 — Non-Current Deffered Revenue slumped 99.58% — and 2018, when it surged 95117.31%.
- Tracing TCRT's Non-Current Deffered Revenue over 5 years: stood at $570000.0 in 2014, then slumped by 45.09% to $313000.0 in 2015, then slipped by 10.22% to $281000.0 in 2016, then slumped by 49.47% to $142000.0 in 2017, then tumbled by 97.18% to $4000.0 in 2018.
- The last three Non-Current Deffered Revenue figures came in at $4000.0 (Q4 2018), $6000.0 (Q3 2018), and $49.5 million (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 4,000.00 |
| Sep 30, 2018 | 6,000.00 |
| Jun 30, 2018 | 49.51 Mn |
| Mar 31, 2018 | 49.04 Mn |
| Dec 31, 2017 | 142,000.00 |
| Sep 30, 2017 | 180,000.00 |
| Jun 30, 2017 | 52,000.00 |
| Mar 31, 2017 | 89,000.00 |
| Dec 31, 2016 | 281,000.00 |
| Sep 30, 2016 | 43.13 Mn |
| Jun 30, 2016 | 423,000.00 |
| Mar 31, 2016 | 276,000.00 |
| Dec 31, 2015 | 313,000.00 |
| Sep 30, 2015 | 379,000.00 |
| Jun 30, 2015 | 869,000.00 |
| Mar 31, 2015 | 958,000.00 |
| Dec 31, 2014 | 570,000.00 |
| Sep 30, 2014 | 665,000.00 |
| Jun 30, 2014 | 730,000.00 |
| Mar 31, 2014 | 792,000.00 |